Masimo vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Masimo Corporation (MASI)

Q3 202622 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

July 202622 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

Latest22 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.